NCT01715714

Brief Summary

Patients with coronary artery disease requiring coronary artery bypass grafting (CABG) are at risk for postoperative complications after surgery. The StaRT-CABG trial is the first large-scale (2,630 patients) that will investigate whether an additional treatment with statins (lipid-lowering medication) in high doses before CABG surgery can reduce the incidence of major post-surgery complications including death, myocardial infarction and stroke. The StaRT-CABG trial will be recruiting patients from 8 cardiac surgery centres in Germany and is expected to provide relevant clinical data on the efficacy of this novel treatment in order to optimize the care for all patients undergoing CABG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,630

participants targeted

Target at P75+ for phase_4 coronary-artery-disease

Timeline
Completed

Started Nov 2012

Longer than P75 for phase_4 coronary-artery-disease

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 18, 2012

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 29, 2012

Completed
9 days until next milestone

Study Start

First participant enrolled

November 7, 2012

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2019

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 27, 2020

Completed
Last Updated

July 22, 2022

Status Verified

July 1, 2022

Enrollment Period

6.5 years

First QC Date

October 18, 2012

Last Update Submit

July 21, 2022

Conditions

Keywords

Coronary Artery DiseaseStatinsCoronary Artery Bypass GraftingCardiac Surgery

Outcome Measures

Primary Outcomes (1)

  • Major adverse cardiocerebral events (MACCE) within 30 days after CABG.

    Composite endpoint consisting of (1) all-cause mortality, (2) non-fatal myocardial infarction (MI) and (3) non-fatal cerebrovascular event (stroke or TIA).

    30 days after Surgery

Secondary Outcomes (6)

  • Major adverse cardiac events

    30 days after Surgery

  • Length of stay

    within the first 15 days after surgery (plus or minus 5 days)

  • Repeat coronary revascularisation

    30 days after surgery

  • Mortality at 12 months

    12 months after surgery

  • Wound Infections

    30 days after surgery

  • +1 more secondary outcomes

Study Arms (2)

Statin Recapture Therapy

ACTIVE COMPARATOR

Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin\* on admission. (\*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)

Drug: Statin Recapture Therapy

Placebo

PLACEBO COMPARATOR

Placebo given orally 12 hrs and 2 hrs before CABG

Drug: Placebo

Interventions

Given 12h and 2h before CABG

Also known as: Simvastatin 80 mg, Atorvastatin 80 mg, Pravastatin 40 mg, Fluvastatin 80 mg
Statin Recapture Therapy

Given 12h and 2h before CABG.

Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients on chronic statin treatment (\>30 days) scheduled for isolated CABG, including on- or off-pump or repeat (redo's) revascularisation procedures
  • Stable or unstable angina, including non ST-segment-elevation acute coronary syndrome (NSTE-ACS)
  • Age ≥ 18 years
  • Written informed consent

You may not qualify if:

  • Any concomitant cardiovascular procedure to CABG (i.e. valve, aortic or carotid surgery)
  • Acute ST-segment-elevation myocardial infarction (STEMI)
  • NSTE-ACS with cardiogenic shock warranting emergent salvage surgery within 12 hrs from hospital admission
  • History of atrial fibrillation or muscle disease (myopathy)
  • Current renal (creatinine\>2x upper limit of normal (ULN), dialysis, kidney transplant) or hepatic dysfunction (AST/ALT\>2x ULN, liver transplant or neoplasm)
  • Inability of oral drug intake

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Heart Center Freiburg-Bad Krozingen

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

Location

Heart Center Bad Neustadt

Bad Neustadt an der Saale, Bavaria, 97616, Germany

Location

University of Aachen

Aachen, North Rhine-Westphalia, 52074, Germany

Location

Heart Center Bad Oeynhausen

Bad Oeynhausen, North Rhine-Westphalia, 32545, Germany

Location

University of Bochum

Bochum, North Rhine-Westphalia, Germany

Location

University of Bonn

Bonn, North Rhine-Westphalia, 53127, Germany

Location

University of Cologne

Cologne, North Rhine-Westphalia, 50924, Germany

Location

University of Essen

Essen, North Rhine-Westphalia, 45122, Germany

Location

University of Muenster

Münster, North Rhine-Westphalia, 48149, Germany

Location

Helios Heart Center Wuppertal

Wuppertal, North Rhine-Westphalia, 42117, Germany

Location

Related Publications (1)

  • Liakopoulos OJ, Kuhn EW, Hellmich M, Kuhr K, Krause P, Reuter H, Thurat M, Choi YH, Wahlers T; StaRT-CABG Investigators. Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial. Am Heart J. 2015 Jul;170(1):46-54, 54.e1-2. doi: 10.1016/j.ahj.2015.04.015. Epub 2015 Apr 17.

Related Links

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

SimvastatinAtorvastatinPravastatinFluvastatin

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

LovastatinNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic CompoundsPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipidsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Oliver J Liakopoulos, MD, PhD

    University of Cologne

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 18, 2012

First Posted

October 29, 2012

Study Start

November 7, 2012

Primary Completion

April 24, 2019

Study Completion

September 27, 2020

Last Updated

July 22, 2022

Record last verified: 2022-07

Locations